Rexahn Pharmaceuticals Inc (RNN)

0.43
0.01 2.70
AMEX : Health Care
Prev Close 0.42
Open 0.42
Day Low/High 0.41 / 0.44
52 Wk Low/High 0.24 / 0.65
Volume 1.33M
Avg Volume 4.20M
Exchange AMEX
Shares Outstanding 237.44M
Market Cap 99.73M
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Rexahn Pharmaceuticals Presents An Update Of The Ongoing Phase IIa Clinical Trial Of RX-3117 In Metastatic Pancreatic Cancer At The American Society Of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium

Rexahn Pharmaceuticals Presents An Update Of The Ongoing Phase IIa Clinical Trial Of RX-3117 In Metastatic Pancreatic Cancer At The American Society Of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium

Evidence of Prolonged Progression Free Survival in Pancreatic Cancer Patients Treated with RX-3117 and for Whom Three or More Prior Therapies had been Ineffective

Rexahn Pharmaceuticals Receives A Notice Of Allowance From The U.S. Patent And Trademark Office For A Patent Covering The Manufacturing Of RX-3117 - A Cancer Cell Specific Anticancer Agent

Rexahn Pharmaceuticals Receives A Notice Of Allowance From The U.S. Patent And Trademark Office For A Patent Covering The Manufacturing Of RX-3117 - A Cancer Cell Specific Anticancer Agent

RX-3117 is Currently in a Phase Ib/IIa Clinical Trial in Patients with Metastatic Pancreatic Cancer

Rexahn Pharmaceuticals Reports Second Quarter 2016 Financial And Operational Results

Rexahn Pharmaceuticals Reports Second Quarter 2016 Financial And Operational Results

Presents Clinical Data for Novel Targeted Cancer Therapeutics, RX-3117, Supinoxin™ and Archexin® at Prominent Oncology Conferences

Rexahn Pharmaceuticals Strengthens Leadership Team

Rexahn Pharmaceuticals Strengthens Leadership Team

Appoints Industry Veteran Lisa Nolan, Ph.D., Chief Business Officer

Rexahn Pharmaceuticals Presents Clinical Data For Three Novel Targeted Oncology Programs At The 2016 American Society Of Clinical Oncology Annual Meeting

Rexahn Pharmaceuticals Presents Clinical Data For Three Novel Targeted Oncology Programs At The 2016 American Society Of Clinical Oncology Annual Meeting

Data Show RX-3117, Archexin® and Supinoxin™ Appear to be Safe and Well Tolerated in Cancer Patients with Advanced and Metastatic Solid Tumors and Show Early Evidence of Clinical Activity

Rexahn Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results

Rexahn Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results

Important Clinical Progress in 2015 Highlights the Potential for Rexahn's Highly-Novel, Targeted Anti-Cancer Therapeutic Approach

8 Biotech Stocks Under $10 Poised for Breakouts

8 Biotech Stocks Under $10 Poised for Breakouts

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Rexahn Pharmaceuticals Completes Stage 1 And Begins Enrollment In Stage 2 Of Archexin® Phase IIa Clinical Trial In Metastatic Renal Cell Carcinoma

Rexahn Pharmaceuticals Completes Stage 1 And Begins Enrollment In Stage 2 Of Archexin® Phase IIa Clinical Trial In Metastatic Renal Cell Carcinoma

Evidence of Dose-Dependent Tumor Reduction Presented at Recent Medical Meetings

Rexahn Pharmaceuticals Announces Supinoxin™ Poster Presentations At The 2016 Gastrointestinal Cancers Symposium

Rexahn Pharmaceuticals Announces Supinoxin™ Poster Presentations At The 2016 Gastrointestinal Cancers Symposium

Additional Preclinical Data Continue to Support Evidence of the Anti-Cancer Effects of Supinoxin™ in Multiple Human Cancer Cell Models

New Preclinical Data For Supinoxin™ Show Oral Administration Produces Clinically Meaningful Tumor Growth Inhibition

New Preclinical Data For Supinoxin™ Show Oral Administration Produces Clinically Meaningful Tumor Growth Inhibition

Supinoxin™ Dose Dependently Inhibits Tumor Cell Growth in a Preclinical Model of Human Renal Cell Carcinoma

Rexahn Pharmaceuticals' Archexin® Shows Dose-Dependent Tumor Reduction In A Phase IIa Clinical Study

Rexahn Pharmaceuticals' Archexin® Shows Dose-Dependent Tumor Reduction In A Phase IIa Clinical Study

Phase IIa Clinical Data Presented at the ASCO 2016 Genitourinary Cancers Symposium